BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 1835621)

  • 1. Prognostic factors in multiple myeloma: a new staging system based on clinical and morphological features.
    Pasqualetti P; Casale R; Collacciani A; Colantonio D
    Eur J Cancer; 1991; 27(9):1123-6. PubMed ID: 1835621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prognostic factors in multiple myeloma. Selection using multivariate analysis].
    Pasqualetti P; Colantonio D; Casale R; Lorenzetti G; Natali G
    Recenti Prog Med; 1989 Oct; 80(10):543-6. PubMed ID: 2602637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Classification and prognostic evaluation in multiple myeloma. A retrospective study of relationship of survivals and responses to chemotherapy to immunological types, 20 single prognostic factors, 15 clinical staging systems, and 6 morphological classifications.
    Pasqualetti P; Colantonio D; Collacciani A; Casale R; Natali G
    Panminerva Med; 1991; 33(2):93-110. PubMed ID: 1923560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Proposal of a new staging system using scoring of multiple myeloma].
    Pasqualetti P; Collacciani A; Casale R; Colantonio D
    Medicina (Firenze); 1989; 9(4):410-3. PubMed ID: 2634228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prognostic evaluation in multiple myeloma. Relationship between immunological types, single prognostic factors, clinical staging systems, morphological classification systems and survival].
    Pasqualetti P; Colantonio D; Casale R; Di Lauro G; Collacciani A; Festuccia V; Trotta A; Natali G
    Ann Ital Med Int; 1990; 5(3 Pt 1):195-204. PubMed ID: 2288822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of a morphologic staging method (myeloma progression score) in multiple myeloma].
    Pasqualetti P; Casale R; Collacciani A; Colantonio D
    Medicina (Firenze); 1989; 9(3):280-2. PubMed ID: 2615598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors in multiple myeloma: selection using Cox's proportional hazard model.
    Pasqualetti P; Collacciani A; Maccarone C; Casale R
    Biomed Pharmacother; 1996; 50(1):29-35. PubMed ID: 8672729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors and staging systems of multiple myeloma:
    Tao ZF; Fu WJ; Yuan ZG; Wang DX; Chen YB; Hou J
    Chin Med J (Engl); 2007 Oct; 120(19):1655-8. PubMed ID: 17935664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple myeloma: relationship between survival and cellular morphology.
    Pasqualetti P; Casale R; Collacciani A; Abruzzo BP; Colantonio D
    Am J Hematol; 1990 Feb; 33(2):145-7. PubMed ID: 2301373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognostic value of the new international staging system in multiple myeloma. Comparison with Durie-Salmon staging system].
    Conté L G; Figueroa M G; Lois V V; Cabrera C ME; León R A; García L H; Rojas R H
    Rev Med Chil; 2008 Jan; 136(1):7-12. PubMed ID: 18483648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of the staging system proposed by Merlini, Waldenström and Jayakar for multiple myeloma.
    Bettini R; Steidl L; Rapazzini P; Giardina G
    Acta Haematol; 1983; 70(6):379-85. PubMed ID: 6417962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters.
    Bhatti SS; Kumar L; Dinda AK; Dawar R
    Am J Hematol; 2006 Sep; 81(9):649-56. PubMed ID: 16845660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of the plasma cell synthesis score in multiple myeloma.
    Pasqualetti P; Collacciani A; Colantonio D; Casale R
    Acta Haematol; 1992; 87(1-2):58-62. PubMed ID: 1585772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple myeloma staging based on the combination of beta-2-microglobulin and albumin: the role of albumin in the model.
    Mihou D; Katodritou E; Zervas K
    Hematology; 2007 Dec; 12(6):527-31. PubMed ID: 17852450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic assessment of the Durie and Salmon staging system in patients with multiple myeloma.
    Spasov E; Goranova V
    Folia Med (Plovdiv); 1998; 40(3B Suppl 3):121-3. PubMed ID: 10206011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Screening of prognostic factors and comparing of staging systems of multiple myeloma].
    Li J; Wu XB; Zhou Y; Wang X; Chen JX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):926-9. PubMed ID: 22931656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients.
    Merlini G; Waldenström JG; Jayakar SD
    Blood; 1980 Jun; 55(6):1011-9. PubMed ID: 7378577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. International staging system for multiple myeloma.
    Greipp PR; San Miguel J; Durie BG; Crowley JJ; Barlogie B; Bladé J; Boccadoro M; Child JA; Avet-Loiseau H; Kyle RA; Lahuerta JJ; Ludwig H; Morgan G; Powles R; Shimizu K; Shustik C; Sonneveld P; Tosi P; Turesson I; Westin J
    J Clin Oncol; 2005 May; 23(15):3412-20. PubMed ID: 15809451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of
    Deng S; Zhang B; Zhou Y; Xu X; Li J; Sang S; Zhang W
    Contrast Media Mol Imaging; 2018; 2018():4198673. PubMed ID: 30154686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extent of disease burden determined with magnetic resonance imaging of the bone marrow is predictive of survival outcome in patients with multiple myeloma.
    Ailawadhi S; Abdelhalim AN; Derby L; Mashtare TL; Miller KC; Wilding GE; Alberico RA; Gottlieb R; Klippenstein DL; Lee K; Chanan-Khan AA
    Cancer; 2010 Jan; 116(1):84-92. PubMed ID: 19862816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.